Completed OBSERVATIONAL NCT01174862

Aspirin Responsiveness and Outcome in Coronary Artery Bypass Graft (CABG) Surgery

Comparative Cohort Study on the Outcome of Patients With Normal and Reduced Acetylsalicylic Acid Responsiveness Undergoing Coronary Artery Bypass Surgery

Sponsor: University Hospital, Basel, Switzerland

Conditions Antithrombotic Drugs [Platelet-aggregation Inhibitors] Causing Adverse Effects in Therapeutic Use Coronary Artery Bypass Graft Triple Vessel Myocardial Ischemia Thrombosis

Updated 6 times since 2017 Last updated: Mar 9, 2015 Started: Jun 30, 2010 Primary completion: Jun 30, 2012 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01174862, this observational or N/A phase trial focuses on Antithrombotic Drugs [Platelet-aggregation Inhibitors] Causing Adverse Effects in Therapeutic Use and Coronary Artery Bypass Graft Triple Vessel and remains completed. Sponsored by University Hospital, Basel, Switzerland, it has been updated 6 times since 2010, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Basel, Switzerland

Data source: University Hospital, Basel, Switzerland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basel, Switzerland